Please read full Prescribing
for NUPLAZID, including Boxed WARNING.

actor portrayal

an essential
to support.Yellow heart reflects Acadia Connect™  Access Support Program for patients, caregivers, and healthcare providers


Acadia Connect® helps ensure that it's easy for your patients to start and continue taking NUPLAZID®. We're here to support you and your enrolled patients with access, insurance, affordability, and prescription assistance.




Acadia Connect® helps ensure that it's easy for your patients to start and continue taking NUPLAZID®. We're here to support you and your enrolled patients with access, insurance, affordability, and prescription assistance.




how Acadia Connect can help.

Your office will be paired with a Patient Access Manager (PAM) to assist you as your patients start and continue treatment. Your patients will be assigned a dedicated Care Coordinator they can turn to for help with insurance coverage, financial assistance, and prescription delivery.
Blue umbrella above a blue heart icon represents Acadia Connect® cost and insurance support for prescriptions


Providing benefits verification, prior authorization assistance, financial support resources, and a free 14-day supply to help patients access their medication*
Blue icon with white 'Rx' text & lines reflect Acadia Connect® coordination with pharmacies for prescriptions


Coordinating with your patient and the pharmacy to help get prescriptions filled and delivered to their preferred location
White heart inside chat icon reflects Acadia Connect® ongoing support and education for prescriptions and insurance coverage


Sharing guidance to help your patients understand the services Acadia Connect offers and access to the medicine you prescribed

*Free 14-day starter supply of NUPLAZID is available to eligible patients enrolled in Acadia Connect and who are prescribed NUPLAZID by their healthcare provider. Acadia Connect patient eligibility and terms and conditions apply.

Your Team

Patient Access Managers

Your Patient Access Manager (PAM) can assist with access or affordability issues and keep you informed if there's an interruption to the treatment regimen you prescribed. This can help your office:

  • Navigate payer coverage and criteria
  • Efficiently resolve patient access issues
  • Stay informed about patients’ insurance status
  • Educate on financial assistance options
  • Address any treatment interruptions

Care Coordinators

Acadia Connect will also provide enrolled patients and caregivers with a dedicated Care Coordinator who can offer personalized guidance for starting and continuing treatment. They will work with you to help your patient and their caregiver:

  • Navigate insurance approvals and authorizations
  • Guide patients to financial assistance options
  • Coordinate with pharmacy to arrange prescription delivery
  • Serve as an ongoing resource to access and affordability support

enroll your patients.

To start these services for you and your patients, complete our simple online prescription and enrollment form.

Connect with us:
8:00 am to
8:00 pm ET
Important Safety Information and Indication for NUPLAZID® (pimavanserin)


  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.